Parnax Lab Ltd.
Snapshot View

26.60 ▼0%

26 July 2021, 04:00:00 P.M.

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.naxparlab.com
Financial Indicators
Market Cap 22.62 Cr.
Earnings per share (EPS) -0.43 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 38.27 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.70 Calculated using Price: 26.60
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.85 Cr. 8,504,866 Shares
FaceValue 10
Company Profile

Parnax Lab, earlier known as Krishnadeep Trade and Investments, incorporated in the year 1982, engages in investing and financial businesses in India. The company is based in Mumbai, India. In 2012 the company has changed its name from Krishna Deep Trade & Investments Ltd. to Parnax Lab Ltd.                                              "

In 2009, Krishna Deep Trade and Investments appointed Rasik Chaturvedi and Dilip Pimparkar as additional directors of the company with effect from February 16, 2009. Further, Rasik Chaturvedi and Dilip Pimparkar have also been inducted on the Audit Committee of the Company.

The registered office of the company is 136, Greet Western Building, Nagindas Master Road Extension, Fort Mumbai, Maharashtra-400001.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
+8.13%
1 Month
+1.53%
3 Month
+14.16%
6 Month
-13.07%
1 Year
+52.00%
2 Year
+8.57%
5 Year
-19.64%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -15.53 9.39 12.70 18.50 9.50 12.51 3.31 9.69 -8.51
Return on Capital Employed (%) -1.95 14.03 14.16 16.35 11.47 13.73 10.49 11.59 3.27
Return on Assets (%) -4.71 2.86 3.47 5.12 3.09 4.48 1.22 3.63 -2.89

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 18 18 21 25 28 31 33 36 33
Non Curr. Liab. 12 17 22 27 23 18 18 23 22
Curr. Liab. 30 25 41 31 29 36 37 36 52
Minority Int. 0 0 0 0 0 0 0 0 0
Equity & Liab. 59 60 83 83 79 86 87 95 107
Non Curr. Assets 38 35 37 45 49 55 51 58 62
Curr. Assets 22 25 46 38 31 31 36 37 46
Misc. Exp. not W/O 0 0 0 0
Total Assets 59 60 83 83 79 86 87 95 107

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 93 56 69 103 71 95 106 109 95
Other Income 1 1 1 1 1 1 1 2 1
Total Income 94 57 70 104 72 96 107 111 96
Total Expenditure -93 -48 -60 -91 -61 -82 -96 -99 -89
PBIDT 1 8 9 13 11 13 11 12 7
Interest -4 -4 -4 -4 -4 -5 -4 -4 -5
Depreciation -2 -2 -2 -3 -3 -4 -4 -4 -4
Taxation 2 -1 -1 -1 -1 -1 -2 -1 -1
Exceptional Items 0
PAT -3 2 2 4 3 4 1 3 -3

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 1 6 0 0 3 16 13 9 9
Cash Fr. Inv. -2 -1 -6 -4 -6 -10 -5 -11 -13
Cash Fr. Finan. -1 -3 6 6 1 -5 -7 1 5
Net Change -1 1 0 1 -2 0 1 -1 0
Cash & Cash Eqvt -1 1 1 2 0 0 1 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 62.59 62.59 62.59 62.59 62.59 62.59 62.59 62.59 62.59
Public 37.41 37.41 37.41 37.41 37.41 37.41 37.41 37.41 37.41
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 14.68 14.68 14.68 14.68 14.68 14.68 14.68 14.68 14.68

Announcements View Details

Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Parnax Lab Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Wed, 14 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Dear Sir

Pursuant to the provisions of Regulation 74(5) or Securities and Exchange Board of India (Depositories and Participants) Regulation 2018 Please find enclosed herewith Compliance Certificate received from the Link Intime India Private Limited Registrar and Share Transfer Agent (RTA) of our Company for the quarter ended 30th June 2021.

You are requested to take the same on record.
Wed, 30 Jun 2021
Outcome Of Board Meeting
Dear Sir

Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) we wish to inform you that in the meeting of the Board of Directors of the Company held on Wednesday 30th June 2021 at its Registered Office the Board inter alia has transacted the following business:
1. Approval of Audited Standalone & Consolidated Financial Results as submitted by statutory auditor of the Company for the quarter and year ended 31st March 2021.

2. Considered and took note of Limited Review Report for the quarter and year ended 31st March 2021.

The Meeting was commenced at 5.00 p.m. and concluded at 9.40 p.m.
Kindly take the same on your record.

Technical Scans View Details

Mon, 26 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Both SRS And ARS Below Zero Both SRS And ARS Below Zero
Close Crossing 50 EMA From Below Close Crossing 50 EMA From Below
5 EMA Crossing 20 EMA From Below 5 EMA Crossing 20 EMA From Below

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 697.50 -0.9%
Divi's Laboratories Ltd. 130,349.05 4,916.55 -0.1%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,345.00 -1.2%
Cipla Ltd. 76,675.40 937.40 -1.4%
Cadila Healthcare Ltd. 61,992.73 610.00 +0.5%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,090.85 -0.2%
Aurobindo Pharma Ltd. 55,837.02 950.05 -0.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 697.50 -0.9%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,916.55 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,345.00 -1.2%
Cipla Ltd. Consolidated 2021-03 31.88 937.40 -1.4%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 610.00 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,090.85 -0.2%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 950.05 -0.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 697.50 -0.9%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,916.55 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,345.00 -1.2%
Cipla Ltd. Consolidated 2021-03 4.18 937.40 -1.4%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 610.00 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,090.85 -0.2%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 950.05 -0.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 697.50 -0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,916.55 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,345.00 -1.2%
Cipla Ltd. Consolidated 2020-03 0.18 937.40 -1.4%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 610.00 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,090.85 -0.2%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 950.05 -0.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 697.50 -0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,916.55 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,345.00 -1.2%
Cipla Ltd. Consolidated 2020-03 10.09 937.40 -1.4%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 610.00 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,090.85 -0.2%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 950.05 -0.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 697.50 -0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,916.55 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,345.00 -1.2%
Cipla Ltd. Consolidated 2020-03 12.53 937.40 -1.4%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 610.00 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,090.85 -0.2%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 950.05 -0.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 697.50 -0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,916.55 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,345.00 -1.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 937.40 -1.4%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 610.00 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,090.85 -0.2%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 950.05 -0.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 697.50 -0.9%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,916.55 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,345.00 -1.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 937.40 -1.4%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 610.00 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,090.85 -0.2%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 950.05 -0.3%